Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland

AIDS

Volumn 12, Issue 10, 1998, Pages 1195-1201

  Gebhardt, Martin ^a   Rickenbach, Martin ^b   Egger, Matthias ^b,c,d  

^a FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Canynge Hall ^*  (United Kingdom)

Author keywords

AIDS; Antiretroviral combination therapy; Projections; Public health surveillance

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOSTATISTICS; CELL COUNT; COHORT ANALYSIS; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH; SWITZERLAND;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 0032500018     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199810000-00012     Document Type: Article

References (29)

1. Swiss Federal Office of Public Health: AIDS and HIV in Switzerland. Epidemiological Situation 7996 [in German and French]. Berne: FOPH; September 1997.
2. European Centre for the Epidemiological Monitoring of AIDS: HIV/AIDS Surveillance in Europe: Quarterly Report no. 52, 31 December 1996. Saint-Maurice: European Centre for the Epidemiological Monitoring of AIDS; 1996.
3. Centers for Disease Control and Prevention: Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR 1997, 46:165-172.
4. Lot F, Pillonel J, Pinget R, et al.: Diminution brutale du nombre de cas de SIDA. Rôle des nouvelles stratégies thérapeutiques? Bull Epidémiol Hebdom 1997, 11:43-45.
5. Robert Koch Institut: AIDS in Deutschland: Situation Ende 1996. Epidemiol Bull 1997, 5:27.
6. Delta Coordinating Committee: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
7. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
8. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
9. CAESAR Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
10. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
11. BHIVA Guidelines Coordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
12. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
13. Karon JM, Green TA, Hanson DL, Ward JW: Estimating the number of AIDS-defining opportunistic illness diagnoses from data collected under the 1993 AIDS surveillance definition. J Acquir Immune Defic Syndr 1997, 16:116-121.
14. Swiss Federal Office of Public Health: Declining AIDS reports: are there really fewer cases? [in German and French]. Bull FOPH 1997, 3:10-12.
15. Ledergerber B, von Overbeck J, Egger M, Lüthy R: The Swiss HIV cohort study: rationale, organisation, and selected baseline characteristics. Soz Praeventivmed 1994, 39:387-394.
16. Von Overbeck J, Egger M, Davey Smith G, et al.: Survival in HIV infection: do sex and category of transmission matter? AIDS 1994, 8:1307-1313.
17. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
18. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-20.
19. Rosenberg PS: A simple correction of AIDS surveillance data for reporting delays. J Acquir Immune Defic Syndr 1990, 3:49-54.
20. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al.: HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ 1994, 309:1537-1542.
21. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. JAMA 1996, 277:145-153.
22. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
23. World Health Organization: Report of the Technical Discussions at the Twenty-First World Health Assembly on 'National and Global Surveillance of Communicable Diseases', 18 May 1968, A21. Geneva: WHO; 1968.
24. Antle CE, Bain LJ: Weibull distribution. In Encyclopedia of Statistical Sciences. Vol 9. New York: John Wiley and Sons; 1988:549-556.
25. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A: Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992, 135:428-437.
26. Rosenberg PS, Goedert JJ, Biggar RJ: Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994, 8:803-810.
27. Rosenberg PS, Gail MH, Carroll RJ: Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med 1992, 11:1633-1655.
28. Alcabes P, Muñoz A, Vlahov D, Friedland GH: Incubation period of human immunodeficiency virus. Epidemiol Rev 1993, 15:303-318.
29. Spiegelhalter D, Thomas A, Best N, Gilks W: BUGS: Bayesian Inference Using Gibbs Sampling. Cambridge: MRC Biostatistics Unit; 1994.